New Japanese Data Bode Well For Shionogi’s OIC Drug
This article was originally published in PharmAsia News
Executive Summary
Shionogi has released the first late-stage clinical results from patients in Japan for its novel opioid-induced constipation drug, the positive data setting the stage for a planned approval filing in this market before the end of the fiscal year.
You may also be interested in...
Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
10 Approvals To Watch For In Early 2017
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.